AR077468A1 - Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa - Google Patents
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasaInfo
- Publication number
- AR077468A1 AR077468A1 ARP100102489A ARP100102489A AR077468A1 AR 077468 A1 AR077468 A1 AR 077468A1 AR P100102489 A ARP100102489 A AR P100102489A AR P100102489 A ARP100102489 A AR P100102489A AR 077468 A1 AR077468 A1 AR 077468A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- ring
- optionally substituted
- independently selected
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Inhibidores de las Trk quinasas y son de utilidad en el tratamiento de enfermedades que se pueden tratar con un inhibidor de Trk quinasa tales como dolor, cáncer, inflamacion, enfermedad neurodegenerativas y ciertas enfermedades infecciosas. Reivindicacion 1: Un compuesto que tiene la formula general (1) o una de sus sales, en donde R1 es H o alquilo C1-6; R2 es H, alquilo C1-6, -fluoroalquilo C1-6, -difluoroalquilo C1-6, -trifluoroalquilo C1-6, -cloroalquilo C1-6, -clorofluoroalquilo C2-6,-difluorocloroalquilo C2-6, -clorohidroxialquilo C2-6, -hidroxialquilo C1-6, -dihidroxialquilo C2-6, -(alquil C1-6)CN, -(alquil C1-6)SO2NH2, -(alquil C1-6)NHSO2(alquilo C1-3), -(alquil C1-6)NH2, -(alquil C1-6)NH(alquilo C1-4), -(alquil C1-6)N(alquilo C1-4)2, -(alquil C1-6)NHC(=O)O(alquilo C1-4), -(alquil C1-6)hetCyc1, -(alquil C1-6) hetAr1, hetAr2, hetCyc2, -O(alquilo C1-6) que está opcionalmente sustituido con halogeno, OH o alcoxi C1-4, -O(cicloalquilo C3-6), Cyc1, -(alquil C1-6)(cicloalquilo C3-6), -(alquil C1-6)(alcoxi C1-4), -(hidroxialquil C1-6)(alcoxi C1-4), un anillo cicloalquilo en puente de 7 miembros opcionalmente sustituido con hidroxialquilo C1-6 o un anillo heterocíclico en puente de 7-8 miembros que tiene 1-2 átomos de nitrogeno del anillo; o NR1R2 forma un anillo azacíclico de 4-6 miembros opcionalmente sustituido con uno o varios sustituyentes seleccionados, de modo independiente, de alquilo C1-6, OH, CO2H, (alquil C1-3)CO2H, -O(alquilo C1-6) e hidroxialquilo C1-6; hetCyc1 es un anillo heterocíclico de 5-6 miembros que tiene 1-2 heteroátomos del anillo seleccionados, de modo independiente, de N y O, en donde hetCyc1 está opcionalmente sustituido con oxo, OH, halogeno o alquilo C1-6; hetCyc2 es un anillo heterocíclico ligado a carbono de 6 miembros que tiene 1-2 heteroátomos del anillo seleccionados, de modo independiente, de N y O, en donde hetCyc2 está opcionalmente sustituido con F, SO2NH2, SO2 (alquilo C1-3) o halogeno; hetAr1 es un anillo heteroarilo de 5 miembros que tiene 1-2 heteroátomos del anillo seleccionados, de modo independiente, de N y O y opcionalmente sustituido con alquilo C1-4; hetAr2 es un anillo heteroarilo de 5-6 miembros que tiene 1-2 átomos de nitrogeno del anillo y está opcionalmente sustituido con uno o varios sustituyentes seleccionados, de modo independiente, de alquilo C1-4, cicloalquilo C3-6, halogeno y OH; Cyc1 es un anillo cicloalquilo de 3-6 miembros que está opcionalmente sustituido con uno o varios sustituyentes seleccionados, de modo independiente, de -alquilo C1-4, -OH, -OMe, -CO2H, -(alquil C1-4)OH, halogeno y CF3; Y es (i) fenilo opcionalmente sustituido con uno o varios sustituyentes seleccionados, de modo independiente, de halogeno, alcoxi C1-4, -CF3, -CHF2, -O(alquil C1-4)hetCyc3, -(alquil C1-4) hetCyc3, -O(alquil C1-4)O(alquilo C1-3 ) y -Odihidroxialquilo C3-6 o (ii) un anillo heteroarilo de 5-6 miembros que tiene un heteroátomo del anillo seleccionado de N y S, en donde dicho anillo heteroarilo está opcionalmente sustituido con uno o varios sustituyentes seleccionados, de modo independiente, de halogeno, -O(alquilo C1-4), alquilo C1-4 y NH2 o (iii) un anillo pirid-2-on-3-ilo opcionalmente sustituido con uno o varios sustituyentes seleccionados, de modo independiente, de halogeno y alquilo C1-4; hetCyc3 es un anillo heterocíclico de 5-6 miembros que tiene 1-2 heteroátomos del anillo seleccionados, de modo independiente, de N y O y opcionalmente sustituido con alquilo C1-6; X es -CH2-, -CH2CH2-, -CH2O- o -CH2NRd-; Rd es H o -alquilo C1-4; R3 es H o -alquilo C1-4; cada R4 está seleccionado, de modo independiente, de halogeno, -alquilo C1-4, -OH, -alcoxi C1-4, -NH2, -NH(alquilo C1-4) y -CH2OH; y n es 0, 1, 2, 3, 4, 5 o 6.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22419609P | 2009-07-09 | 2009-07-09 | |
US34676710P | 2010-05-20 | 2010-05-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR077468A1 true AR077468A1 (es) | 2011-08-31 |
Family
ID=42732102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100102489A AR077468A1 (es) | 2009-07-09 | 2010-07-08 | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
Country Status (22)
Country | Link |
---|---|
US (6) | US8791123B2 (es) |
EP (2) | EP3299372B1 (es) |
JP (3) | JP5716021B2 (es) |
KR (3) | KR101997055B1 (es) |
CN (3) | CN106008523B (es) |
AR (1) | AR077468A1 (es) |
AU (1) | AU2010271270C1 (es) |
CA (2) | CA3013618C (es) |
CL (1) | CL2012000059A1 (es) |
CO (1) | CO6612183A2 (es) |
CR (2) | CR20120065A (es) |
ES (2) | ES2655899T3 (es) |
IL (1) | IL217414A (es) |
MX (2) | MX364157B (es) |
MY (1) | MY162180A (es) |
NZ (1) | NZ598086A (es) |
RU (2) | RU2584157C2 (es) |
SG (2) | SG177553A1 (es) |
TW (1) | TWI503321B (es) |
UY (1) | UY32782A (es) |
WO (1) | WO2011006074A1 (es) |
ZA (1) | ZA201200982B (es) |
Families Citing this family (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2738026C (en) | 2008-09-22 | 2017-01-24 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
PT2725028T (pt) | 2008-10-22 | 2016-08-31 | Array Biopharma Inc | Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk |
PE20131197A1 (es) | 2008-10-31 | 2013-11-06 | Genentech Inc | Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen |
RS56995B1 (sr) | 2008-12-19 | 2018-05-31 | Vertex Pharma | Derivati pirazina korisni kao inhibitori atr kinaze |
UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
PL2918588T3 (pl) * | 2010-05-20 | 2017-10-31 | Array Biopharma Inc | Związki makrocykliczne jako inhibitory kinazy TRK |
WO2012034095A1 (en) * | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
GEP20156285B (en) * | 2011-02-25 | 2015-05-11 | Aierem Elelsi | Compounds and compositions as trk inhibitors |
SI2712358T1 (sl) | 2011-05-13 | 2017-03-31 | Array Biopharma, Inc. | Spojine pirolidinil sečnine, pirolidinil tiosečnine in pirolidinil gvanidina kot inhibitorji kinaze trka |
PT2940017T (pt) | 2011-09-30 | 2019-10-31 | Vertex Pharma | Processos para a produção de compostos úteis como inibidores de atr quinase |
CN108464983A (zh) | 2011-09-30 | 2018-08-31 | 沃泰克斯药物股份有限公司 | 用atr抑制剂治疗胰腺癌和非小细胞肺癌 |
SG11201405561RA (en) * | 2012-03-09 | 2014-10-30 | Lexicon Pharmaceuticals Inc | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE |
NZ700580A (en) | 2012-04-05 | 2016-07-29 | Vertex Pharma | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
SI2841428T1 (sl) | 2012-04-24 | 2018-12-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
MA37975B2 (fr) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
WO2014078322A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078372A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
SI2920166T1 (sl) * | 2012-11-13 | 2017-01-31 | Array Biopharma, Inc. | Spojine uree, tiouree, gvanidina in cianogvanidina, primerne za zdravljenje bolečine |
CN104781255B (zh) * | 2012-11-13 | 2017-10-24 | 阵列生物制药公司 | 作为trka激酶抑制剂的n‑吡咯烷基、n’‑吡唑基‑脲、硫脲、胍和氰基胍化合物 |
WO2014078417A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9969694B2 (en) | 2012-11-13 | 2018-05-15 | Array Biopharma Inc. | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9340546B2 (en) | 2012-12-07 | 2016-05-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
RU2667907C9 (ru) * | 2013-02-19 | 2019-01-31 | Оно Фармасьютикал Ко., Лтд. | ИНГИБИРУЮЩЕЕ Trk СОЕДИНЕНИЕ |
PT2989106T (pt) | 2013-04-25 | 2017-03-15 | Beigene Ltd | Compostos heterocíclicos fundidos como inibidores da proteína quinase |
EP3628749A1 (en) | 2013-07-30 | 2020-04-01 | Blueprint Medicines Corporation | Ntrk2 fusions |
TW201542550A (zh) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
PL3702373T3 (pl) | 2013-09-13 | 2022-12-05 | Beigene Switzerland Gmbh | Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne |
EP3057953B1 (en) | 2013-10-17 | 2018-08-15 | Vertex Pharmaceuticals Incorporated | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
TWI663159B (zh) * | 2013-12-10 | 2019-06-21 | 美商健臻公司 | 原肌球蛋白相關之激酶(trk)抑制劑 |
WO2015104602A2 (en) | 2014-01-08 | 2015-07-16 | Wockhardt Limited | A process for the preparation of anagliptin and its intermediates thereof |
DK3572416T3 (da) | 2014-01-24 | 2022-12-12 | Turning Point Therapeutics Inc | Diaryl-makrocykler som modulatorer af proteinkinaser |
IN2014MU01191A (es) | 2014-03-29 | 2015-10-02 | Wockhardt Ltd | |
CR20160583A (es) | 2014-05-15 | 2017-02-23 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoxietil)pirrolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)urea como inhibidor de trka cinasa |
EP3145929B1 (en) | 2014-05-23 | 2021-01-13 | F. Hoffmann-La Roche AG | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors |
WO2015181747A1 (en) | 2014-05-28 | 2015-12-03 | Novartis Ag | Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors |
AU2015271030B2 (en) | 2014-06-05 | 2019-05-16 | Vertex Pharmaceuticals Incorporated | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo [1,5-a] pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, the preparation of said compound and different solid forms thereof |
PL3157566T3 (pl) | 2014-06-17 | 2019-10-31 | Vertex Pharma | Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr |
KR102003754B1 (ko) | 2014-07-03 | 2019-07-25 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
JP5979335B2 (ja) * | 2014-08-18 | 2016-08-24 | 小野薬品工業株式会社 | Trk阻害化合物の酸付加塩 |
EA032872B1 (ru) * | 2014-09-17 | 2019-07-31 | Онкодизайн С.А. | Макроциклические ингибиторы rip2-киназы |
US10570135B2 (en) | 2014-11-06 | 2020-02-25 | Lysosomal Therapeutics Inc. | Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders |
KR102649887B1 (ko) | 2014-11-16 | 2024-03-22 | 어레이 바이오파마 인크. | (s)-n-(5-((r)-2-(2,5-디플루오로페닐)-피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복스아미드 히드로겐 술페이트의 결정질 형태 |
US9701681B2 (en) | 2014-12-15 | 2017-07-11 | Cmg Pharmaceutical Co., Ltd. | Fused ring heteroaryl compounds and their use as Trk inhibitors |
CA2988423A1 (en) | 2015-06-01 | 2016-12-08 | Loxo Oncology, Inc. | Methods of diagnosing and treating cancer |
WO2017004342A1 (en) | 2015-07-02 | 2017-01-05 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
EA035049B1 (ru) | 2015-07-16 | 2020-04-22 | Аррэй Байофарма Инк. | СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ |
DK3325488T3 (da) * | 2015-07-21 | 2020-09-14 | Turning Point Therapeutics Inc | Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer |
CA2995997A1 (en) | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
JP7187308B2 (ja) | 2015-09-30 | 2022-12-12 | バーテックス ファーマシューティカルズ インコーポレイテッド | Dna損傷剤とatr阻害剤との組み合わせを使用する、がんを処置するための方法 |
CN108697708A (zh) | 2015-10-26 | 2018-10-23 | 洛克索肿瘤学股份有限公司 | Trk抑制剂抗性癌症中的点突变以及与此相关的方法 |
WO2017073706A1 (ja) * | 2015-10-30 | 2017-05-04 | 中外製薬株式会社 | ジヒドロナフト[2,3-b]ベンゾフラン誘導体 |
SG10201912607SA (en) * | 2015-11-19 | 2020-02-27 | Blueprint Medicines Corp | Compounds and compositions useful for treating disorders related to ntrk |
MA44612A (fr) | 2016-04-04 | 2019-02-13 | Loxo Oncology Inc | Méthodes de traitement de cancers pédiatriques |
TN2018000335A1 (en) | 2016-04-04 | 2020-01-16 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
MX2018012208A (es) | 2016-04-06 | 2019-03-28 | Lysosomal Therapeutics Inc | Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. |
KR20230104752A (ko) | 2016-04-06 | 2023-07-10 | 비알 - 알&디 인베스트먼츠, 에스.에이. | 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물및 의학적 장애의 치료에서의 그의 용도 |
MX2018012207A (es) | 2016-04-06 | 2019-03-28 | Lysosomal Therapeutics Inc | Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. |
SG11201809693SA (en) | 2016-05-05 | 2018-11-29 | Lysosomal Therapeutics Inc | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
CN110049987B (zh) | 2016-05-18 | 2022-02-18 | 阵列生物制药公司 | 制备化合物及其盐的方法 |
WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
KR20230162137A (ko) | 2016-08-16 | 2023-11-28 | 베이진 스위찰랜드 게엠베하 | (s)-7-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)-4,5,6,7-테트라-하이드로피라졸로 [1,5-a] 피리미딘-3-카르복스아미드의 제조 및 그 용도 |
TWI739887B (zh) | 2016-08-19 | 2021-09-21 | 英屬開曼群島商百濟神州有限公司 | 使用包含btk抑制劑的組合產品治療癌症 |
TW201815418A (zh) | 2016-09-27 | 2018-05-01 | Vertex Pharma | 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法 |
KR101881650B1 (ko) * | 2016-10-02 | 2018-07-24 | 재단법인대구경북과학기술원 | 뇌유래신경성장인자를 과발현하는 우울증 동물모델 및 이의 제조방법 |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
CA3041942C (en) | 2016-10-28 | 2023-03-14 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor |
CN108003161B (zh) * | 2016-10-28 | 2020-10-09 | 正大天晴药业集团股份有限公司 | 神经营养因子酪氨酸激酶受体抑制剂 |
EP3571203B1 (en) | 2017-01-18 | 2023-06-07 | Array BioPharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) -PIPERIDINE-4-YL) -2- (4-PHENOXYPHENYL) -4,5,6,7-TETRAHYDROPYRAZOLO [1,5-A ] PYRIMIDINE-3-CARBOXAMIDE, MANUFACTURING AND USES THEREOF |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
AU2018274577A1 (en) | 2017-05-22 | 2019-10-10 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
CA3066518A1 (en) | 2017-06-26 | 2019-01-03 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
CN109824566A (zh) * | 2017-07-19 | 2019-05-31 | 浙江师范大学 | 一种(r)-2-(2,5-二氟苯基)吡咯烷的合成方法 |
CA3070621A1 (en) * | 2017-07-28 | 2019-01-31 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
JP6916562B2 (ja) * | 2017-08-11 | 2021-08-11 | テリジーン リミテッドTeligene Ltd. | 化合物、その薬学的に許容される塩、溶媒和物、立体異性体及び互変異性体、並びに薬物組成物、過剰増殖性障害治療剤、過剰増殖性障害予防剤、薬物、癌治療剤、癌予防剤、及びキナーゼシグナル伝達調節剤 |
WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
MA50456A (fr) | 2017-10-26 | 2020-09-02 | Array Biopharma Inc | Formulations d'un inhibiteur de kinase trk macrocyclique |
US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
TWI802635B (zh) | 2018-01-18 | 2023-05-21 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物 |
JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての置換ピラゾリル[4,3-c]ピリジン化合物 |
US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
CN110156813B (zh) * | 2018-02-13 | 2023-07-25 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
PL3762368T3 (pl) | 2018-03-08 | 2022-06-06 | Incyte Corporation | ZWIĄZKI AMINOPIRAZYNODIOLOWE JAKO INHIBITORY PI3K-γ |
CN111936500B (zh) * | 2018-03-14 | 2023-09-01 | 重庆复尚源创医药技术有限公司 | 作为TRK激酶抑制剂的取代的(2-氮杂双环[3.1.0]己-2-基)吡唑[1,5-a]嘧啶和咪唑[1,2-b]哒嗪化合物 |
EP3773725A1 (en) | 2018-03-29 | 2021-02-17 | Loxo Oncology Inc. | Treatment of trk-associated cancers |
CN110294761B (zh) * | 2018-06-08 | 2020-09-08 | 南京雷正医药科技有限公司 | 作为Trk激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物 |
CN110627812B (zh) | 2018-06-25 | 2022-10-11 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
CA3224949A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
WO2020038457A1 (zh) * | 2018-08-23 | 2020-02-27 | 珠海联邦制药股份有限公司 | 作为JAK抑制剂的[1,2,4]***并[1,5-a]吡啶类化合物及其应用 |
CN110857304B (zh) * | 2018-08-24 | 2021-05-18 | 北京富龙康泰生物技术有限公司 | Trk抑制剂、其制备方法和用途 |
CA3111984A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
CN113271940A (zh) * | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
CN111171049B (zh) * | 2018-11-09 | 2021-06-04 | 山东轩竹医药科技有限公司 | 酪氨酸激酶抑制剂及其用途 |
CN111269233A (zh) * | 2018-12-05 | 2020-06-12 | 上海轶诺药业有限公司 | 一类咪唑并芳环类化合物的制备和应用 |
CN113166156B (zh) * | 2018-12-07 | 2024-02-27 | 贝达药业股份有限公司 | 酪氨酸激酶抑制剂、组成及其方法 |
EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
WO2020172505A1 (en) | 2019-02-22 | 2020-08-27 | Regeneron Pharmaceuticals, Inc. | Rodents having genetically modified sodium channels and methods of use thereof |
CN111718351B (zh) * | 2019-03-19 | 2021-10-12 | 华中师范大学 | 含氧取代吡唑并嘧啶化合物和药物组合物及其应用 |
CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
CN111848626B (zh) * | 2019-04-30 | 2021-11-30 | 江苏柯菲平医药股份有限公司 | Trk激酶抑制剂及其用途 |
JP7420403B2 (ja) * | 2019-05-08 | 2024-01-23 | ティーワイケー メディシンズ インコーポレーテッド | キナーゼ阻害剤として使用される化合物およびその応用 |
WO2021027503A1 (zh) * | 2019-08-12 | 2021-02-18 | 罗欣药业(上海)有限公司 | 三环类化合物、其制备方法、中间体及应用 |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
CN111138437B (zh) * | 2019-12-04 | 2021-03-05 | 杭州华东医药集团新药研究院有限公司 | 取代的吡唑并[1,5-a]嘧啶氨基酸衍生物及其用途 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN115210232B (zh) * | 2020-01-22 | 2024-03-01 | 上海齐鲁制药研究中心有限公司 | 吡唑并杂芳环类化合物及其应用 |
CA3169832A1 (en) * | 2020-02-13 | 2021-08-19 | Zhuhai United Laboratories Co., Ltd. | Use of jak inhibitors in preparation of drugs for treatment of jak kinase related diseases |
CN114437077B (zh) * | 2020-11-04 | 2024-01-30 | 浙江同源康医药股份有限公司 | 用作激酶抑制剂的化合物及其应用 |
WO2021249450A1 (zh) * | 2020-06-11 | 2021-12-16 | 贝达药业股份有限公司 | 酪氨酸激酶抑制剂的盐型、晶型、药物组合物及其用途 |
CN111777549A (zh) * | 2020-07-07 | 2020-10-16 | 中瀚(齐河县)生物医药科技有限公司 | 一种2-甲氧基-3-溴-5-氟吡啶的合成工艺 |
WO2022018695A1 (en) | 2020-07-24 | 2022-01-27 | Genzyme Corporation | Pharmaceutical compositions comprising venglustat |
CN113563343B (zh) * | 2020-07-27 | 2022-05-24 | 杭州邦顺制药有限公司 | 取代的吡唑并[1,5-a]嘧啶化合物及其用途 |
CN112645955B (zh) * | 2020-12-24 | 2022-11-04 | 四川国康药业有限公司 | 一种[1,2,4]***并[4,3-b]哒嗪类化合物及其制备方法和用途 |
US20240092759A1 (en) * | 2021-01-08 | 2024-03-21 | Yale University | Non-Covalent Inhibitors of the Main Protease of SARS-CoV-2 and Methods of Use |
CN112979646B (zh) * | 2021-03-08 | 2022-01-14 | 北京富龙康泰生物技术有限公司 | 一种咪唑并吡啶类衍生物 |
CN114907247A (zh) * | 2022-04-21 | 2022-08-16 | 上海陶术生物科技有限公司 | 吡咯烷中间体及吡咯烷盐类化合物的制备方法 |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (255)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ234143A (en) | 1989-06-28 | 1991-10-25 | Mcneil Ppc Inc | Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents |
KR100229343B1 (ko) | 1993-11-30 | 1999-11-01 | 윌리암스 로저 에이 | 염증치료용 치환 피라졸일벤젠술폰아미드 |
US5430021A (en) | 1994-03-18 | 1995-07-04 | Pharmavene, Inc. | Hydrophobic drug delivery systems |
US5844092A (en) | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
CA2206201A1 (en) | 1996-05-29 | 1997-11-29 | Yoshiaki Isobe | Pyrazole derivatives and their pharmaceutical use |
JP3898296B2 (ja) | 1996-08-28 | 2007-03-28 | ポーラ化成工業株式会社 | ピロロピラゾロピリミジン化合物及びこれを有効成分とする医薬 |
AU7079998A (en) | 1997-04-25 | 1998-11-24 | Takeda Chemical Industries Ltd. | Condensed pyridazine derivatives, their production and use |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6534085B1 (en) | 1999-09-23 | 2003-03-18 | Bioresponse L.L.C. | Phytochemicals for promoting weight loss |
DK1292680T3 (da) | 2000-06-22 | 2010-03-08 | Genentech Inc | Agonist-anti-TrkC monoklonale antistoffer |
TWI312347B (en) | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
CA2448956C (en) | 2001-05-30 | 2017-10-03 | Genentech, Inc. | Anti-ngf antibodies for the treatment of various disorders |
US7101572B2 (en) | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
MXPA04010441A (es) | 2002-04-23 | 2005-02-14 | Shionogi & Co | Derivado de pirazolo[1,5-a]pirimidina e inhibidor de nad(p)h oxidasa que contiene el mismo. |
US7449488B2 (en) | 2002-06-04 | 2008-11-11 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
ITMI20021620A1 (it) | 2002-07-23 | 2004-01-23 | Novuspharma Spa | Composto ad ativita' antitumorale |
JP4024624B2 (ja) * | 2002-08-26 | 2007-12-19 | 富士通株式会社 | 半導体装置の製造方法及び製造装置 |
CN1880317B (zh) * | 2002-09-04 | 2012-10-10 | 先灵公司 | 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶 |
EP1537116B1 (en) | 2002-09-04 | 2010-06-02 | Schering Corporation | Pyrazolopyrimidines suitable for the treatment of cancer diseases |
US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
AU2003299651A1 (en) | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
US7262199B2 (en) | 2002-12-11 | 2007-08-28 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
US7514446B2 (en) | 2003-02-20 | 2009-04-07 | Smithkline Beecham Corporation | Pyrimidine compounds |
US20070037150A1 (en) | 2003-02-21 | 2007-02-15 | The Johns Hopkins University | Tyrosine kinome |
JP2004277337A (ja) * | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | ピラゾロ[1,5−a]ピリミジン誘導体 |
WO2004087707A1 (en) * | 2003-03-31 | 2004-10-14 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
EP1615667A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist |
US20060094699A1 (en) | 2003-04-11 | 2006-05-04 | Kampen Gita Camilla T | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
EP1615697A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof |
US20070042941A1 (en) | 2003-04-28 | 2007-02-22 | Mitsuomi Hirashima | Galectin 9-inducing factors |
PA8603801A1 (es) | 2003-05-27 | 2004-12-16 | Janssen Pharmaceutica Nv | Derivados de la quinazolina |
JP2005008581A (ja) * | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
EA009517B1 (ru) | 2003-06-27 | 2008-02-28 | Байер Кропсайенс Аг | Пиразолопиримидины |
TWI382031B (zh) | 2003-07-15 | 2013-01-11 | Amgen Inc | 作為選擇性神經生長因子(ngf)通道抑制劑之人類抗-ngf中和抗體 |
US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
US7169918B2 (en) | 2003-10-27 | 2007-01-30 | Genelabs Technologies, Inc. | Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives |
MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
TW200529849A (en) | 2003-11-28 | 2005-09-16 | Novartis Ag | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
US7799772B2 (en) | 2003-12-18 | 2010-09-21 | Janssen Pharmaceutica N.V. | Pyrido-and pyrimidopyrimidine derivatives as anti-profilerative agents |
PL1696920T3 (pl) | 2003-12-19 | 2015-03-31 | Plexxikon Inc | Związki i sposoby opracowywania modulatorów Ret |
WO2005068424A1 (en) | 2004-01-20 | 2005-07-28 | Cell Therapeutics Europe S.R.L. | Indolinone derivatives as receptor tyrosine kinase ihibitors |
US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
WO2005099363A2 (en) | 2004-03-26 | 2005-10-27 | Whitehead Institute For Biomedical Research | Methods of diagnosing, preventing and treating cancer metastasis |
CN1938311A (zh) | 2004-03-30 | 2007-03-28 | 因特蒙公司 | 作为病毒复制抑制剂的大环化合物 |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
AU2005304784B2 (en) | 2004-11-04 | 2011-03-24 | Vertex Pharmaceuticals Incorporated | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
JO3088B1 (ar) | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
DE102005003687A1 (de) | 2005-01-26 | 2006-07-27 | Sphingo Tec Gmbh | Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation |
DK1853602T3 (da) | 2005-02-16 | 2010-09-20 | Astrazeneca Ab | Kemiske forbindelser |
CN101119996A (zh) * | 2005-02-16 | 2008-02-06 | 阿斯利康(瑞典)有限公司 | 化学化合物 |
DK1869049T3 (da) | 2005-03-21 | 2009-05-18 | Lilly Co Eli | Imidazopyridazinforbindelser |
CN101208093A (zh) | 2005-04-27 | 2008-06-25 | 阿斯利康(瑞典)有限公司 | 吡唑-嘧啶衍生物在治疗疼痛中的用途 |
US20080287437A1 (en) | 2005-05-16 | 2008-11-20 | Astrazeneca Ab | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors |
CN100406650C (zh) | 2005-06-05 | 2008-07-30 | 徐斌 | 一种抗特大变位的模块式梳型桥梁伸缩缝装置 |
ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
DK1893612T3 (da) | 2005-06-22 | 2011-11-21 | Plexxikon Inc | Pyrrol [2,3-B]pyridin-derivater som proteinkinasehæmmere |
US20070025540A1 (en) | 2005-07-07 | 2007-02-01 | Roger Travis | Call center routing based on talkativeness |
GEP20105124B (en) | 2005-07-25 | 2010-11-25 | Array Biopharma Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
US20100216798A1 (en) | 2005-07-29 | 2010-08-26 | Astellas Pharma Inc | Fused heterocycles as lck inhibitors |
CN101232871A (zh) | 2005-08-03 | 2008-07-30 | 伊士曼化工公司 | 生育酚聚乙二醇琥珀酸酯粉末及其制备方法 |
AU2006283592A1 (en) | 2005-08-22 | 2007-03-01 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
JP5366548B2 (ja) | 2005-08-25 | 2013-12-11 | クレアビリス・セラピューティクス・エスピーエー | K‐252aおよびその誘導体のポリマー結合体 |
DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
US20070082900A1 (en) | 2005-10-06 | 2007-04-12 | Schering Corporation | Methods for inhibiting protein kinases |
AR057979A1 (es) | 2005-10-06 | 2008-01-09 | Schering Corp | PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS. |
CA2624772C (en) * | 2005-10-11 | 2011-11-29 | Centre National De La Recherche Scientifique (Cnrs) | Compounds and kits for the detection and the quantification of cell apoptosis |
KR20080056295A (ko) | 2005-10-11 | 2008-06-20 | 인터뮨, 인크. | C형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법 |
AU2006304875B2 (en) | 2005-10-21 | 2013-01-17 | Exelixis, Inc. | Pyrazolo-pyrimidines as casein kinase II (CK2) modulators |
WO2007057399A2 (en) | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Treatment of cancer with indole derivatives |
GB0524436D0 (en) | 2005-11-30 | 2006-01-11 | Novartis Ag | Organic compounds |
JP5474354B2 (ja) | 2005-12-30 | 2014-04-16 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
WO2007084815A2 (en) | 2006-01-19 | 2007-07-26 | Janssen Pharmaceutica, N.V. | Substituted thienopyrimidine kinase inhibitors |
EP1978958A4 (en) | 2006-01-24 | 2009-12-02 | Merck & Co Inc | INHIBITION OF TYROSINE KINASE RET |
KR100846988B1 (ko) | 2006-03-06 | 2008-07-16 | 제일약품주식회사 | 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물 |
MX2008011220A (es) | 2006-03-07 | 2008-09-11 | Array Biopharma Inc | Compuestos de pirazol heterobiciclicos y metodos de uso. |
ZA200808966B (en) | 2006-03-27 | 2010-03-31 | Nerviano Medical Sciences Srl | Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors |
GB0606805D0 (en) | 2006-04-04 | 2006-05-17 | Novartis Ag | Organic compounds |
WO2007129161A2 (en) | 2006-04-26 | 2007-11-15 | F. Hoffmann-La Roche Ag | Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor |
CN101443009A (zh) | 2006-05-18 | 2009-05-27 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
US7389632B2 (en) | 2006-06-10 | 2008-06-24 | Uhlmann Pac-Systeme Gmbh & Co. Kg | Apparatus for distributing small objects in a fill station |
EP1873157A1 (en) * | 2006-06-21 | 2008-01-02 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
TWI419889B (zh) * | 2006-07-05 | 2013-12-21 | Mitsubishi Tanabe Pharma Corp | 吡唑并〔1,5-a〕嘧啶化合物 |
US20100029619A1 (en) | 2006-08-04 | 2010-02-04 | Takeda Pharmaceutical Company Limted | Fused heterocyclic compound |
US7531539B2 (en) | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
CN101594909A (zh) | 2006-09-07 | 2009-12-02 | 比奥根艾迪克Ma公司 | 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 |
WO2008031551A2 (en) | 2006-09-12 | 2008-03-20 | Novartis Forschungsstiftung, Zweigniederlassung | Non-neuroendocrine cancer therapy |
CA2664378A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as pi3k lipid kinase inhibitors |
CN101522682A (zh) | 2006-10-30 | 2009-09-02 | 诺瓦提斯公司 | 作为抗炎剂的杂环化合物 |
EP2086979B1 (en) | 2006-11-06 | 2015-06-03 | Tolero Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
EP2094701A2 (en) | 2006-12-21 | 2009-09-02 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20080234267A1 (en) | 2007-03-20 | 2008-09-25 | Karen Elizabeth Lackey | Compounds and Methods of Treatment |
US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
JP2010522716A (ja) | 2007-03-28 | 2010-07-08 | イノバシア・アクチボラゲット | ステアロイル−CoAデサチュラーゼのインヒビターとしてのピラゾロ[1,5−A]ピリミジン |
US8138181B2 (en) | 2007-04-03 | 2012-03-20 | Array Biopharma Inc. | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
WO2008137794A1 (en) | 2007-05-04 | 2008-11-13 | Irm Llc | Compounds and compositions as c-kit and pdgfr kinase inhibitors |
CA2687909C (en) | 2007-06-21 | 2015-09-15 | Janssen Pharmaceutica Nv | Indolin-2-ones and aza-indolin-2-ones |
AR067478A1 (es) | 2007-07-09 | 2009-10-14 | Astrazeneca Ab | Compuestos derivados de morfolina pirimidina |
US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
EP2178861B1 (en) | 2007-07-19 | 2014-08-20 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
CN103923072B (zh) | 2007-07-20 | 2017-05-31 | 内尔维阿诺医学科学有限公司 | 作为具有激酶抑制剂活性的取代的吲唑衍生物 |
WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
CN101827609B (zh) | 2007-08-10 | 2014-03-12 | 里珍纳龙药品有限公司 | 抗人神经生长因子的高亲和力人抗体 |
CN101883774A (zh) | 2007-10-16 | 2010-11-10 | 惠氏有限责任公司 | 噻吩并嘧啶和吡唑并嘧啶化合物及其用作mtor激酶和pi3激酶抑制剂的用途 |
EA201000603A1 (ru) | 2007-10-23 | 2010-12-30 | Новартис Аг | ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ |
WO2009060197A1 (en) | 2007-11-08 | 2009-05-14 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazopyridazines for use as protein kinase inhibitors |
CN101970440A (zh) | 2007-11-28 | 2011-02-09 | 先灵公司 | 作为蛋白激酶抑制剂的2-氟吡唑并[1,5-a]嘧啶类 |
WO2009071480A2 (en) | 2007-12-04 | 2009-06-11 | Nerviano Medical Sciences S.R.L. | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors |
WO2009092049A1 (en) | 2008-01-17 | 2009-07-23 | Irm Llc | Improved anti-trkb antibodies |
US20090227556A1 (en) | 2008-01-31 | 2009-09-10 | Eisai R&D Management Co., Ltd. | Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives |
EP2254886B1 (en) | 2008-03-28 | 2016-05-25 | Nerviano Medical Sciences S.r.l. | 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
CN102056927B (zh) | 2008-05-13 | 2014-06-25 | Irm责任有限公司 | 作为激酶抑制剂的稠合含氮杂环及其组合物 |
PE20091846A1 (es) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
KR101257158B1 (ko) | 2008-05-23 | 2013-04-23 | 노파르티스 아게 | 단백질 티로신 키나제 억제제로서의 퀴놀린 및 퀴녹살린의 유도체 |
JP5767965B2 (ja) | 2008-06-10 | 2015-08-26 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼを調節する5h−ピロロ[2,3−b]ピラジン誘導体、およびその適応症 |
EP2323664B1 (en) | 2008-07-29 | 2015-01-07 | Nerviano Medical Sciences S.r.l. | Use of a cdk inhibitor for the treatment of glioma |
WO2010031816A1 (en) | 2008-09-19 | 2010-03-25 | Nerviano Medical Sciences S.R.L. | 3,4 DIHYDRO-2H-PYRROLO[1,2-a]PYRAZIN-1-ONE DERIVATIVES |
CA2738026C (en) | 2008-09-22 | 2017-01-24 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
PT2725028T (pt) | 2008-10-22 | 2016-08-31 | Array Biopharma Inc | Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk |
PE20131197A1 (es) | 2008-10-31 | 2013-11-06 | Genentech Inc | Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen |
US8912194B2 (en) | 2008-11-24 | 2014-12-16 | Nerviano Medical Sciences S.R.L. | CDK inhibitor for the treatment of mesothelioma |
JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
ES2637174T3 (es) | 2009-02-12 | 2017-10-11 | Cell Signaling Technology, Inc. | Expresión de ROS mutante en el cáncer de hígado humano |
WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
EP3045457B1 (en) | 2009-06-15 | 2018-05-09 | Nerviano Medical Sciences S.r.l. | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
ES2524576T3 (es) | 2010-01-29 | 2014-12-10 | Nerviano Medical Sciences S.R.L. | Derivados de 6,7-dihidroimidazo[1,5-a]pirazin-8(5H)-ona como moduladores de proteína cinasa |
JP2013519706A (ja) | 2010-02-18 | 2013-05-30 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 癌転移を予防するための方法 |
WO2011127219A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
US8543395B2 (en) | 2010-05-18 | 2013-09-24 | Shazam Entertainment Ltd. | Methods and systems for performing synchronization of audio with corresponding textual transcriptions and determining confidence values of the synchronization |
PL2918588T3 (pl) | 2010-05-20 | 2017-10-31 | Array Biopharma Inc | Związki makrocykliczne jako inhibitory kinazy TRK |
EP2606067B1 (en) | 2010-08-19 | 2018-02-21 | Zoetis Belgium S.A. | Anti-ngf antibodies and their use |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
JP2014005206A (ja) | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
KR20190112175A (ko) | 2010-12-01 | 2019-10-02 | 앨더바이오 홀딩스 엘엘씨 | 항―ngf 조성물 및 그의 용도 |
ES2586588T3 (es) | 2011-01-26 | 2016-10-17 | Nerviano Medical Sciences S.R.L. | Derivados tricíclicos, procedimiento para su preparación y su uso como inhibidores de quinasa |
WO2012101032A1 (en) | 2011-01-26 | 2012-08-02 | Nerviano Medical Sciences S.R.L. | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors |
PL2672967T3 (pl) | 2011-02-07 | 2019-04-30 | Plexxikon Inc | Związki i sposoby modulacji kinaz i wskazania ku temu |
US9199979B2 (en) | 2011-02-24 | 2015-12-01 | Nerviano Medical Sciences S.R.L. | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
GEP20156285B (en) | 2011-02-25 | 2015-05-11 | Aierem Elelsi | Compounds and compositions as trk inhibitors |
US9284298B2 (en) | 2011-04-11 | 2016-03-15 | Nerviano Medical Sciences S.R.L. | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
ES2616458T3 (es) | 2011-04-19 | 2017-06-13 | Nerviano Medical Sciences S.R.L. | Pirimidil pirroles sustituidos activos como inhibidores de quinasas |
KR101953272B1 (ko) | 2011-05-12 | 2019-02-28 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 키나제 억제제로서 활성인 치환된 인다졸 유도체 |
SI2712358T1 (sl) | 2011-05-13 | 2017-03-31 | Array Biopharma, Inc. | Spojine pirolidinil sečnine, pirolidinil tiosečnine in pirolidinil gvanidina kot inhibitorji kinaze trka |
EP2736514B1 (en) | 2011-07-28 | 2017-10-18 | Nerviano Medical Sciences S.r.l. | Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors |
JP6063945B2 (ja) | 2011-10-07 | 2017-01-18 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤としての4−アルキル置換3,4−ジヒドロピロロ[1,2−a]ピラジン−1(2H)−オン誘導体 |
ES2639064T3 (es) | 2011-10-07 | 2017-10-25 | Nerviano Medical Sciences S.R.L. | Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1(2h)-ona sustituidos como inhibidores de cinasa |
WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
RU2014119150A (ru) | 2011-11-14 | 2015-12-27 | Тесаро, Инк. | Модулирование некоторых тирозинкиназ |
US9045479B2 (en) | 2011-12-12 | 2015-06-02 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
TW201350479A (zh) | 2012-04-26 | 2013-12-16 | Ono Pharmaceutical Co | Trk阻害化合物 |
JP2013226108A (ja) | 2012-04-27 | 2013-11-07 | Astellas Pharma Inc | 新規ntrk2活性化変異の検出法 |
RU2602071C2 (ru) | 2012-05-23 | 2016-11-10 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида |
TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物 |
DK2872491T3 (da) | 2012-07-11 | 2021-08-09 | Blueprint Medicines Corp | Inhibitorer af fibroblastvækstfaktorreceptoren |
EP2689778A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
CN104507923B (zh) | 2012-08-02 | 2018-02-09 | 内尔维阿诺医学科学有限公司 | 作为激酶抑制剂的取代的吡咯类活性剂 |
EP2890815B1 (en) | 2012-08-31 | 2019-03-20 | The Regents of the University of Colorado | Methods for diagnosis and treatment of cancer |
CN104703600A (zh) | 2012-09-07 | 2015-06-10 | 埃克塞里艾克西斯公司 | 用于治疗肺腺癌的met、vegfr和ret的抑制剂 |
US20140084039A1 (en) | 2012-09-24 | 2014-03-27 | Electro Scientific Industries, Inc. | Method and apparatus for separating workpieces |
JP2014082984A (ja) | 2012-10-23 | 2014-05-12 | Astellas Pharma Inc | 新規ntrk2活性化変異の検出法 |
WO2014071419A2 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
CA2890207A1 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
JP6326057B2 (ja) | 2012-11-07 | 2018-05-16 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 置換ピリミジニルおよびピリジニル−ピロロピリジノン、これらの調製のための方法、およびキナーゼ阻害剤としてのこれらの使用 |
WO2014078322A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9969694B2 (en) | 2012-11-13 | 2018-05-15 | Array Biopharma Inc. | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
SI2920166T1 (sl) | 2012-11-13 | 2017-01-31 | Array Biopharma, Inc. | Spojine uree, tiouree, gvanidina in cianogvanidina, primerne za zdravljenje bolečine |
US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078417A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
CN104781255B (zh) | 2012-11-13 | 2017-10-24 | 阵列生物制药公司 | 作为trka激酶抑制剂的n‑吡咯烷基、n’‑吡唑基‑脲、硫脲、胍和氰基胍化合物 |
US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078372A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
BR112015002626A2 (pt) | 2012-11-29 | 2017-09-26 | Yeda Res & Dev | métodos para prevenção de metástases tumorais, tratamento e prognostico do câncer e identificação dos agentes que são inibidores da metástase putativa |
US9447135B2 (en) | 2012-12-14 | 2016-09-20 | University Of Kentucky Research Foundation | Semi-synthetic mithramycin derivatives with anti-cancer activity |
US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
RU2667907C9 (ru) | 2013-02-19 | 2019-01-31 | Оно Фармасьютикал Ко., Лтд. | ИНГИБИРУЮЩЕЕ Trk СОЕДИНЕНИЕ |
US20160010068A1 (en) | 2013-02-22 | 2016-01-14 | Boris C. Bastian | Fusion polynucleotides and fusion polypeptides associated with cancer and particularly melanoma and their uses as therapeutic and diagnostic targets |
WO2014134096A1 (en) | 2013-02-27 | 2014-09-04 | Oregon Health & Science University | Methods of treating cancers characterized by aberrent ros1 activity |
WO2014152777A2 (en) | 2013-03-15 | 2014-09-25 | Insight Genetics, Inc. | Methods and compositions for the diagnosis and treatment of cancers resistant to ros1 inhibitors |
EP2968551B1 (en) | 2013-03-15 | 2021-05-05 | The Trustees of Columbia University in the City of New York | Fusion proteins and methods thereof |
MA38394B1 (fr) | 2013-03-15 | 2018-04-30 | Glaxosmithkline Ip Dev Ltd | Dérivés pyridine utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret) |
CN113337604A (zh) | 2013-03-15 | 2021-09-03 | 莱兰斯坦福初级大学评议会 | 循环核酸肿瘤标志物的鉴别和用途 |
WO2014150751A2 (en) | 2013-03-15 | 2014-09-25 | Novartis Ag | Biomarkers associated with brm inhibition |
US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
US20140315199A1 (en) | 2013-04-17 | 2014-10-23 | Life Technologies Corporation | Gene fusions and gene variants associated with cancer |
US10072298B2 (en) | 2013-04-17 | 2018-09-11 | Life Technologies Corporation | Gene fusions and gene variants associated with cancer |
EP2997030B1 (en) | 2013-05-14 | 2017-08-09 | Nerviano Medical Sciences S.R.L. | Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors |
JP2016520131A (ja) | 2013-05-30 | 2016-07-11 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼ調節のための化合物、およびその適応 |
CA2917735C (en) | 2013-07-11 | 2017-04-18 | Betta Pharmaceuticals Co., Ltd | Protein tyrosine kinase modulators and methods of use |
WO2015012397A1 (ja) | 2013-07-26 | 2015-01-29 | 公益財団法人がん研究会 | Ntrk3融合体の検出法 |
US10875930B2 (en) | 2013-07-30 | 2020-12-29 | Blueprint Medicines Corporation | PIK3C2G fusions |
EP3628749A1 (en) | 2013-07-30 | 2020-04-01 | Blueprint Medicines Corporation | Ntrk2 fusions |
WO2015039006A1 (en) | 2013-09-16 | 2015-03-19 | The General Hospital Corporation | Methods of treating cancer |
DK3057969T3 (en) | 2013-10-17 | 2018-09-24 | Blueprint Medicines Corp | COMPOSITIONS USED FOR TREATMENT OF DISEASES RELATED TO ENZYMETE KIT |
US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
WO2015061229A1 (en) | 2013-10-24 | 2015-04-30 | Georgetown University | Methods and compositions for treating cancer |
EP3060560A1 (en) | 2013-10-25 | 2016-08-31 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
WO2015064621A1 (ja) | 2013-10-29 | 2015-05-07 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
DK3572416T3 (da) | 2014-01-24 | 2022-12-12 | Turning Point Therapeutics Inc | Diaryl-makrocykler som modulatorer af proteinkinaser |
DK3102555T3 (da) | 2014-02-05 | 2021-08-09 | VM Oncology LLC | Sammensætninger af forbindelser og anvendelser deraf |
TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ros1突變癌細胞之分子 |
WO2015161274A1 (en) | 2014-04-18 | 2015-10-22 | Blueprint Medicines Corporation | Pik3ca fusions |
WO2015161277A1 (en) | 2014-04-18 | 2015-10-22 | Blueprint Medicines Corporation | Met fusions |
CR20160583A (es) | 2014-05-15 | 2017-02-23 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoxietil)pirrolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)urea como inhibidor de trka cinasa |
WO2015183836A1 (en) | 2014-05-27 | 2015-12-03 | Brian Haynes | Compositions, methods, and uses related to ntrk2-tert fusions |
WO2015183837A1 (en) | 2014-05-27 | 2015-12-03 | Brian Haynes | Compositions, methods, and uses related to ntrk2-tert fusions |
US20170114415A1 (en) | 2014-05-30 | 2017-04-27 | The Regents Of The University Of Colorado, A Body Corporate | Activating ntrk1 gene fusions predictive of kinase inhibitor therapy |
EP3155118A1 (en) | 2014-06-10 | 2017-04-19 | Blueprint Medicines Corporation | Pkn1 fusions |
WO2015191666A2 (en) | 2014-06-10 | 2015-12-17 | Blueprint Medicines Corporation | Raf1 fusions |
US10370725B2 (en) | 2014-07-17 | 2019-08-06 | Blueprint Medicines Corporation | FGR fusions |
WO2016011147A1 (en) | 2014-07-17 | 2016-01-21 | Blueprint Medicines Corporation | Prkc fusions |
EP3169808B1 (en) | 2014-07-17 | 2019-05-22 | Blueprint Medicines Corporation | Trio:tert fusion in cancer |
KR20170042614A (ko) | 2014-08-01 | 2017-04-19 | 파마싸이클릭스 엘엘씨 | Btk 저해제를 이용한 치료에 대한 dlbcl의 반응을 예측하기 위한 바이오마커 |
WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
JP5979335B2 (ja) | 2014-08-18 | 2016-08-24 | 小野薬品工業株式会社 | Trk阻害化合物の酸付加塩 |
MX2017004810A (es) | 2014-10-14 | 2017-10-16 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas. |
WO2016075224A1 (en) | 2014-11-14 | 2016-05-19 | Nerviano Medical Sciences S.R.L. | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
KR102649887B1 (ko) | 2014-11-16 | 2024-03-22 | 어레이 바이오파마 인크. | (s)-n-(5-((r)-2-(2,5-디플루오로페닐)-피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복스아미드 히드로겐 술페이트의 결정질 형태 |
US20170356052A1 (en) | 2014-11-18 | 2017-12-14 | Blueprint Medicines Corporation | Prkacb fusions |
US9701681B2 (en) | 2014-12-15 | 2017-07-11 | Cmg Pharmaceutical Co., Ltd. | Fused ring heteroaryl compounds and their use as Trk inhibitors |
MY190974A (en) | 2015-05-20 | 2022-05-25 | Massachusetts Gen Hospital | Shared neoantigens |
US20180177792A1 (en) | 2015-05-29 | 2018-06-28 | Ignyta, Inc. | Compositions and methods for treating patients with rtk mutant cells |
CA2988423A1 (en) | 2015-06-01 | 2016-12-08 | Loxo Oncology, Inc. | Methods of diagnosing and treating cancer |
US9782400B2 (en) | 2015-06-19 | 2017-10-10 | Macau University Of Science And Technology | Oncogenic ROS1 and ALK kinase inhibitor |
AU2015101722A4 (en) | 2015-06-19 | 2016-05-19 | Macau University Of Science And Technology | Oncogenic ros1 and alk kinase inhibitor |
GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
WO2017004342A1 (en) | 2015-07-02 | 2017-01-05 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
CN108697708A (zh) | 2015-10-26 | 2018-10-23 | 洛克索肿瘤学股份有限公司 | Trk抑制剂抗性癌症中的点突变以及与此相关的方法 |
US20170224662A1 (en) | 2016-01-22 | 2017-08-10 | The Medicines Company | Aqueous Formulations and Methods of Preparation and Use Thereof |
WO2017155018A1 (ja) | 2016-03-11 | 2017-09-14 | 小野薬品工業株式会社 | Trk阻害剤抵抗性の癌治療剤 |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
TN2018000335A1 (en) | 2016-04-04 | 2020-01-16 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
EP3445361A1 (en) | 2016-04-19 | 2019-02-27 | Exelixis, Inc. | Triple negative breast cancer treatment method |
WO2017201156A1 (en) | 2016-05-18 | 2017-11-23 | Duke University | Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab |
CN110049987B (zh) | 2016-05-18 | 2022-02-18 | 阵列生物制药公司 | 制备化合物及其盐的方法 |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
MA50456A (fr) | 2017-10-26 | 2020-09-02 | Array Biopharma Inc | Formulations d'un inhibiteur de kinase trk macrocyclique |
-
2010
- 2010-07-08 AR ARP100102489A patent/AR077468A1/es not_active Application Discontinuation
- 2010-07-09 JP JP2012519764A patent/JP5716021B2/ja not_active Expired - Fee Related
- 2010-07-09 CN CN201610388362.1A patent/CN106008523B/zh active Active
- 2010-07-09 CN CN201811635133.0A patent/CN110003214B/zh active Active
- 2010-07-09 MX MX2015000539A patent/MX364157B/es unknown
- 2010-07-09 CA CA3013618A patent/CA3013618C/en active Active
- 2010-07-09 CA CA2767648A patent/CA2767648C/en active Active
- 2010-07-09 TW TW099122737A patent/TWI503321B/zh not_active IP Right Cessation
- 2010-07-09 NZ NZ598086A patent/NZ598086A/en not_active IP Right Cessation
- 2010-07-09 ES ES10732606.8T patent/ES2655899T3/es active Active
- 2010-07-09 MY MYPI2012000087A patent/MY162180A/en unknown
- 2010-07-09 EP EP17199899.0A patent/EP3299372B1/en active Active
- 2010-07-09 SG SG2012001178A patent/SG177553A1/en unknown
- 2010-07-09 EP EP10732606.8A patent/EP2451812B1/en active Active
- 2010-07-09 KR KR1020187037088A patent/KR101997055B1/ko active IP Right Grant
- 2010-07-09 AU AU2010271270A patent/AU2010271270C1/en not_active Ceased
- 2010-07-09 CN CN201080040095.XA patent/CN102596957B/zh active Active
- 2010-07-09 WO PCT/US2010/041538 patent/WO2011006074A1/en active Application Filing
- 2010-07-09 MX MX2012000513A patent/MX2012000513A/es active IP Right Grant
- 2010-07-09 KR KR1020127003458A patent/KR101784977B1/ko active IP Right Grant
- 2010-07-09 ES ES17199899T patent/ES2774654T3/es active Active
- 2010-07-09 RU RU2012104493/04A patent/RU2584157C2/ru not_active IP Right Cessation
- 2010-07-09 SG SG10201603095TA patent/SG10201603095TA/en unknown
- 2010-07-09 KR KR1020177027763A patent/KR101933123B1/ko active IP Right Grant
- 2010-07-09 RU RU2016114128A patent/RU2016114128A/ru not_active Application Discontinuation
- 2010-07-09 US US13/382,858 patent/US8791123B2/en active Active
- 2010-07-09 UY UY0001032782A patent/UY32782A/es not_active Application Discontinuation
-
2012
- 2012-01-08 IL IL217414A patent/IL217414A/en not_active IP Right Cessation
- 2012-01-09 CL CL2012000059A patent/CL2012000059A1/es unknown
- 2012-02-08 CO CO12022116A patent/CO6612183A2/es active IP Right Grant
- 2012-02-08 CR CR20120065A patent/CR20120065A/es unknown
- 2012-02-09 ZA ZA2012/00982A patent/ZA201200982B/en unknown
- 2012-12-17 CR CR20120641A patent/CR20120641A/es unknown
-
2014
- 2014-07-01 US US14/321,246 patent/US9682979B2/en active Active
-
2015
- 2015-01-09 JP JP2015002767A patent/JP6114765B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-09 US US15/401,913 patent/US9782415B2/en active Active
- 2017-01-09 US US15/401,895 patent/US9796724B2/en active Active
- 2017-02-08 JP JP2017020927A patent/JP2017082004A/ja not_active Withdrawn
- 2017-10-04 US US15/724,601 patent/US10251889B2/en active Active
-
2019
- 2019-04-08 US US16/377,514 patent/US10758542B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR077468A1 (es) | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa | |
AR074052A1 (es) | Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa | |
PE20211411A1 (es) | Compuestos de anillo fusionado | |
AR079541A1 (es) | Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms | |
PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
PE20050691A1 (es) | Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa | |
PE20070855A1 (es) | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas | |
PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
AR065556A1 (es) | Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida | |
AR081919A1 (es) | Compuestos macrociclicos como inhibidores de quinasa trk y procesos de preparacion de los mismos | |
AR056691A1 (es) | Derivados pirrolopirimidina como inhibidores de syk | |
PE20080841A1 (es) | Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion | |
AR040477A1 (es) | Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos | |
MX368066B (es) | Derivados de quinazolin-4-ona sustituida. | |
PE20151413A1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
AR086367A1 (es) | Compuestos de pirrolidinil urea y pirrolidinil tiourea como inhibidores de cinasa trka | |
PE20141974A1 (es) | Compuestos de heterociclilo | |
PA8783501A1 (es) | Derivados de quinaxolina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus | |
ECSP10010585A (es) | Compuestos de 2- imido- 3- metil pirrolo pirimidinona fenilo- sustituidos como inhibidores bace- 1, composiciones, y su uso | |
PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
PE20110411A1 (es) | Imidazopiridazinacarbonitrilos como inhibidores de quinasa | |
AR033678A1 (es) | Derivados de quinolina, procedimiento para prepararlos, uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados | |
AR053778A1 (es) | Compuestos de quinazolina para el tratamiento de desordenes mediados por la proteina quinasa | |
AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal | ||
FB | Suspension of granting procedure |